Alphatec (ATEC)
NASDAQ:ATEC
Want to see ATEC full AI Analyst Report?
ATEC Stock Chart & Stats
$11.10
$0.31(3.32%)
At close: 4:00 PM EST
$11.10
$0.31(3.32%)
Day’s Range― - ―
52-Week Range$6.82 - $23.29
Previous CloseN/A
Volume519.80K
Average Volume (3M)4.06M
Market Cap
$1.25B
Enterprise Value$1.66B
Total Cash (Recent Filing)$139.91M
Total Debt (Recent Filing)$603.06M
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Jul 30, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding153,789,300
10 Day Avg. Volume2,405,808
30 Day Avg. Volume4,056,974
Financial Highlights & Ratios
PEG Ratio1.46
Price to Book (P/B)87.63
Price to Sales (P/S)4.13
P/FCF Ratio1.14K
Enterprise Value/Market Cap1.32
Enterprise Value/Revenue2.10
Enterprise Value/Gross Profit3.22
Enterprise Value/Ebitda-1.22K
Forecast
1Y Price Target
$18.50Price Target Upside66.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)0.31
Revenue Forecast (FY)$883.68M
Bulls Say, Bears Say
Bulls Say
Surgeon & Procedure AdoptionSustained surgeon adoption and rising procedure volumes indicate expanding clinical footprint and stickiness. A growing installed user base supports recurring implant and instrument sales, increases lifetime surgeon value, and creates durable revenue growth as new users broaden case volume and implant pull‑through over time.
High & Expanding Gross MarginsConsistently high gross margins and margin expansion signal a structurally profitable product mix and manufacturing/pricing leverage. With operating expenses growing well below revenue, the company can convert additional scale into durable EBITDA gains and reinvestment capacity for R&D and sales.
Financing & Free‑cash‑flow TrajectoryRefinancing that lowers interest expense and extends maturities materially improves financial flexibility, reducing refinancing risk. Combined with a recent cash‑flow turn (positive OCF/TTM FCF progress), this creates a more durable platform to fund growth and delever over the medium term.
Bears Say
High LeverageVery high absolute debt and a thin equity base leave the company vulnerable to operational setbacks. Leverage constrains strategic optionality, increases interest coverage risk, and amplifies downside in slower growth periods, meaning continued cash generation is required to avoid balance‑sheet stress.
Persistent GAAP LossesDespite margin and EBITDA improvement, GAAP profitability remains negative. Ongoing net losses erode equity, limit free cash build, and reduce resilience to cyclical or execution shocks, delaying meaningful deleveraging and the shift to self‑funded investment without external financing.
EOS Execution & Mix PressureExecution issues for the EOS platform and weaker procedure economics from lower biologics attachment compress near‑term revenue visibility and mix. Persistent delivery/install delays and lower per‑case economics can slow implant pull‑through and delay realization of system economics over multiple quarters.
Alphatec Holdings News
ATEC FAQ
What was Alphatec’s price range in the past 12 months?
Alphatec lowest stock price was $6.82 and its highest was $23.29 in the past 12 months.
What is Alphatec’s market cap?
Alphatec’s market cap is $1.25B.
When is Alphatec’s upcoming earnings report date?
Alphatec’s upcoming earnings report date is Jul 30, 2026 which is in 47 days.
How were Alphatec’s earnings last quarter?
Alphatec released its earnings results on May 05, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.022 by $0.022.
Is Alphatec overvalued?
According to Wall Street analysts Alphatec’s price is currently Undervalued.
Does Alphatec pay dividends?
Alphatec does not currently pay dividends.
What is Alphatec’s EPS estimate?
Alphatec’s EPS estimate is 0.07.
How many shares outstanding does Alphatec have?
Alphatec has 153,789,300 shares outstanding.
What happened to Alphatec’s price movement after its last earnings report?
Alphatec reported an EPS of $0 in its last earnings report, beating expectations of -$0.022. Following the earnings report the stock price went down -31.672%.
Which hedge fund is a major shareholder of Alphatec?
Currently, no hedge funds are holding shares in ATEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alphatec Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.50 (66.67% Upside)
$18.50 (66.67% Upside)
Blogger Sentiment
Bullish
ATEC Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.69%
12-Months-Change
Fundamentals
Return on Equity
-443.09%
Trailing 12-Months
Asset Growth
1.78%
Trailing 12-Months
Company Description
Alphatec
Alphatec Holdings, Inc. is a medical technology firm dedicated to engineering and advancing solutions for the surgical management of spinal conditions. Its product array includes the Alpha InformatiX platform, notably the SafeOp Neural InformatiX System, which is engineered to reduce the likelihood of nerve injury during surgery. For access and positioning, Alphatec offers systems such as the Sigma transforaminal lumbar interbody fusion pedicle-based access system, the Sigma PTP Access and Patient Positioning System, and the Squadron lateral retractor, all designed to optimize surgical outcomes. The company's robust line of spinal fixation devices features the Invictus Spinal Fixation System, capable of addressing various thoracolumbar pathologies, alongside its minimally invasive SingleStep System and adaptable Modular Fixation Systems, which enhance screw modularity. Further fixation options include the OsseoScrew system for spinal column restoration and the comprehensive Arsenal spinal fixation platform, catering to a spectrum of degenerative to deformity procedures. Alphatec also provides anterior lumbar plating solutions like the Aspida Anterior Lumbar Plating System for interbody fusion and the AMP Anti-Migration Plate, in addition to cervical fixation options such as the OCT Spinal Fixation System, the Trestle Luxe Anterior Cervical Plate System, and the Insignia Anterior Cervical Plate System. Its portfolio extends to interbody implants, including IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Implants. A comprehensive suite of biologics is also available, featuring Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier. The company additionally offers EOS imaging products. Alphatec Holdings markets its diverse product range throughout the United States via a network of independent distributors and its own direct sales force. Established in 1990, the company's headquarters are located in Carlsbad, California.
ATEC Company Deck
ATEC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely constructive operational and financial picture: healthy top-line growth (14% total, 17% surgical), strong surgeon and case adoption (23% and 21%), margin expansion, and substantial adjusted EBITDA improvement (97% YoY). Key near-term execution challenges center on EOS system deliveries and installation timing, mix-driven revenue-per-case pressure, and temporary working-capital investments (inventory/instruments). Management updated EOS near-term expectations but maintained surgical and adjusted EBITDA guidance, emphasized corrective actions (sales/marketing/support hires), and closed a favorable refinancing to improve the capital structure. On balance, the positive scale, profitability, and strategic momentum outweigh the execution-related headwinds noted for the quarter.View all ATEC earnings summariesATEC Stock 12 Month Forecast
Average Price Target
$18.50
▲(66.67% Upside)
Technical Analysis
Ownership Overview
39.61% Insiders
17.33% Mutual Funds
18.31% Other Institutional Investors
15.24% Public Companies and
Individual Investors